Drug intelligence / Profile preview

SNS-102

Development stage: Preclinical
Lead developer: Sensei Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SNS-102 is a conditionally active monoclonal antibody developed by Sensei Biotherapeutics. It targets V-Set and Immunoglobulin Domain Containing 4 (VSIG4), a B7 family-related protein that is often overexpressed on macrophages within the tumor microenvironment and acts as a potent inhibitor of T cell activity. The drug is designed to be active specifically in the low-pH tumor microenvironment, aiming to block VSIG4 and thereby unleash an immune response against solid tumors while minimizing off-target toxicities.

Targets

VSIG4 (V-set and immunoglobulin domain-containing protein 4)

Beyond the preview

Go deeper on SNS-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNS-102.

Explore the full profile